Get the Stockscreener App
1.81
4.74%
-0.09
Beyondspring Inc stock is traded at $1.81, with a volume of 102.93K.
It is down -4.74% in the last 24 hours and down -7.18% over the past month.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
See More
Previous Close:
$1.90
Open:
$1.84
24h Volume:
102.93K
Relative Volume:
0.45
Market Cap:
$75.25M
Revenue:
$1.88M
Net Income/Loss:
$-15.57M
P/E Ratio:
-4.525
EPS:
-0.4
Net Cash Flow:
$-50.09M
1W Performance:
-16.97%
1M Performance:
-7.18%
6M Performance:
-41.80%
1Y Performance:
+18.30%
1-Day Range:
$1.785
$1.98
1-Week Range:
$1.785
$2.44
52-Week Range:
$0.98
$3.44
Beyondspring Inc Stock (BYSI) Company Profile
Name
Beyondspring Inc
Sector
Industry
Phone
646-528-4184
Address
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY
Compare BYSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BYSI
Beyondspring Inc
|
1.83 | 78.13M | 1.88M | -15.57M | -50.09M | -0.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.12 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.64 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
847.62 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
394.91 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
165.60 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-21 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-02-21 | Downgrade | Jefferies | Buy → Hold |
| Dec-01-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-01-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-09-21 | Initiated | Robert W. Baird | Outperform |
| Aug-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-05-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-11-21 | Initiated | BofA Securities | Buy |
| Dec-29-20 | Initiated | Evercore ISI | Outperform |
| Feb-07-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | Nomura | Buy |
| Dec-03-19 | Initiated | William Blair | Outperform |
| Jul-10-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-19 | Downgrade | Maxim Group | Buy → Hold |
| Oct-25-18 | Reiterated | Maxim Group | Buy |
View All
Beyondspring Inc Stock (BYSI) Latest News
Pharma News: Will BeyondSpring Inc. stock outperform tech sector in 2025Quarterly Trade Summary & Low Risk Investment Opportunities - moha.gov.vn
Beyondspring Delays Second Closings of Share Sale - TipRanks
BeyondSpring Inc. Announces Preferred Share Purchase Agreement - TradingView — Track All Markets
BeyondSpring (NASDAQ: BYSI) now expects SEED share Second Closings in 1H 2026 - Stock Titan
BYSI: Recent Business Developments Shape Market Outlook - StocksToTrade
BeyondSpring Inc. Stock Shows Upward Spike As Earnings Report Uncovers Surprises - StocksToTrade
BeyondSpring Stock Faces Challenges Amid Recent Market Dynamics - timothysykes.com
BeyondSpring Inc. Faces Financial Pressure in the Pharmaceutical Market - timothysykes.com
BYSI Stock Shows Turbulence Amid Financial Uncertainty - StocksToTrade
BYSI Stock Volatility Amidst Strategic Developments and Market Shifts - StocksToTrade
BYSI’s Stock Roller Coaster: What Happens Next? - StocksToTrade
BeyondSpring Inc.’s Market Shift: Analyzing Financial Trends and Price Movements - timothysykes.com
BeyondSpring’s Stock Gains Steam Amid Market Developments - timothysykes.com
BeyondSpring (BYSI) Stock :Surges 5% as New Plinabulin Data Strengthens Case for Global NSCLC Registration Path - CoinCentral
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 - marketscreener.com
BYSI: BeyondSpring's Plinabulin Shows Promising Results in Phase 3 Trial - GuruFocus
BeyondSpring stock rises after positive Asian subset data from lung cancer trial - Investing.com Nigeria
BeyondSpring reports positive Asian subset data for lung cancer drug - Investing.com
BeyondSpring reports positive Asian subset data for lung cancer drug By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path - GlobeNewswire
BeyondSpring’s Plinabulin combination shows survival benefit in NSCLC - TipRanks
BeyondSpring (BYSI) Reports Promising Results for Plinabulin in Lung Cancer Study - GuruFocus
BeyondSpring Announces Positive Phase 3 DUBLIN-3 Results for Plinabulin in NSCLC Patients Post Anti-PD-(L)1 Therapy and Plans for Global DUBLIN-4 Trial - Quiver Quantitative
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025 - marketscreener.com
BeyondSpring (NASDAQ: BYSI) DUBLIN-3 finds 15.8-month OS, fewer brain mets in NSCLC - Stock Titan
Why 22nd Century Group Inc stock could benefit from AI revolutionTrade Ideas & Accurate Buy Signal Notifications - moha.gov.vn
BeyondSpring Inc. Reports Q3 2025 Earnings and Strategic Shift - MSN
What Wall Street predicts for BeyondSpring Inc. stock priceMarket Growth Report & Fast Momentum Entry Tips - Newser
Is BeyondSpring Inc. stock in correction or buying zone2025 Technical Overview & Safe Capital Growth Tips - Newser
BeyondSpring (NASDAQ:BYSI) Shares Down 3.6%Should You Sell? - MarketBeat
Nasdaq Moves: What Wall Street predicts for BeyondSpring Inc stock priceMarket Weekly Review & Precise Entry and Exit Recommendations - BỘ NỘI VỤ
BYSI SEC FilingsBeyondspring Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Will BeyondSpring Inc. stock benefit from AI adoptionTrade Volume Summary & Daily Entry Point Alerts - BỘ NỘI VỤ
Dividend Watch: Why BeyondSpring Inc. stock could benefit from AI revolutionProduct Launch & AI Based Buy and Sell Signals - moha.gov.vn
BeyondSpring Reports Third‐Quarter 2025 Financial Results and Provides Corporate Update - 富途牛牛
BeyondSpring Completes $2 Million Securities Agreement - TipRanks
Why BeyondSpring Inc. stock remains on watchlistsJuly 2025 Volume & High Accuracy Swing Entry Alerts - newser.com
How BeyondSpring Inc. stock valuations compare to rivalsOil Prices & Accurate Technical Buy Alerts - newser.com
How currency fluctuations impact BeyondSpring Inc. stock2025 EndofYear Setup & Proven Capital Preservation Methods - newser.com
Will BeyondSpring Inc. stock reach all time highs in 20252025 Fundamental Recap & High Accuracy Swing Trade Signals - newser.com
Is BeyondSpring Inc. stock a top pick in earnings season2025 Stock Rankings & Daily Chart Pattern Signals - newser.com
Using Bollinger Bands to evaluate BeyondSpring Inc.July 2025 Trade Ideas & Smart Money Movement Alerts - newser.com
Is BeyondSpring Inc. forming a bottoming base2025 Trade Ideas & Fast Gain Stock Tips - newser.com
What earnings revisions data tells us about BeyondSpring Inc.July 2025 Catalysts & Safe Investment Capital Preservation Plans - newser.com
[424B5] BeyondSpring Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Beyondspring Inc Stock (BYSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.38%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):